Literature DB >> 26508025

Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma.

Yuan Chang1, Qiang Fu2, Le Xu3, Lin Zhou1, Zheng Liu2, Yuanfeng Yang1, Zongming Lin4, Jiejie Xu5.   

Abstract

Growing evidence indicates that systemic inflammation involves in cancer development and progression. Preoperative lymphocyte to monocyte ratio (LMR) has been estimated as an independent prognostic factor of various cancers. We investigated the prognostic value of LMR in nonmetastatic clear cell renal cell carcinoma (ccRCC) patients after surgery. We retrospectively recruited 430 consecutive patients with nonmetastatic ccRCC (T1-3N0M0) who underwent curative nephrectomy between 2008 and 2009 at a single center in China. Lymphocyte and monocyte counts were obtained at hospitalization before surgery. Preoperative LMR as a continuous variable and as a dichotomized variable at a level of 3.25, which was the 25th percentile value, were analyzed in unvariable and multivariable Cox regression models, respectively. Concordance index (C-index) was calculated to assess predictive accuracy. Kaplan-Meier method was applied to compare survival curves. As both of the continuous and dichotomized variable, decreased preoperative LMR was proven to be independent prognostic factors of recurrence-free survival (P = 0.039 and P = 0.003, respectively) and overall survival (P = 0.002 and P < 0.001, respectively). Further examination revealed that the dichotomized LMR could enhance the predictive accuracy of each of the existing prognostic models among intermediate-risk to high-risk patients. The preoperative LMR is an independent prognostic factor of recurrence-free survival and overall survival for nonmetastatic ccRCC patients after surgery, and it can be used in tandem with established prognostic systems to further enhance outcome prediction in intermediate-risk to high-risk patients.

Entities:  

Keywords:  Biomarker; Inflammation; Overall survival; Recurrence-free survival; Renal cell carcinoma

Mesh:

Year:  2015        PMID: 26508025     DOI: 10.1007/s13277-015-4300-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Lei Luo; Fang-Ning Wan; Yi-Ping Zhu; Li-Jiang Sun; Ding-Wei Ye
Journal:  Tumour Biol       Date:  2015-06-02

4.  Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma.

Authors:  Le Xu; Yu Zhu; Lian Chen; Huimin An; Weijuan Zhang; Guomin Wang; Zongming Lin; Jiejie Xu
Journal:  Ann Surg Oncol       Date:  2014-03-11       Impact factor: 5.344

5.  Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma.

Authors:  Shogo Kumagai; Satoshi Marumo; Tsuyoshi Shoji; Minoru Sakuramoto; Tatsuya Hirai; Takafumi Nishimura; Nobuyoshi Arima; Motonari Fukui; Cheng-Long Huang
Journal:  Lung Cancer       Date:  2014-06-28       Impact factor: 5.705

Review 6.  Treatment options for metastatic renal cell carcinoma: a review.

Authors:  Uzma Athar; Teresa C Gentile
Journal:  Can J Urol       Date:  2008-04       Impact factor: 1.344

7.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

8.  Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Ji-Feng Feng; Jin-Shi Liu; Ying Huang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

9.  The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.

Authors:  M Stotz; M Pichler; G Absenger; J Szkandera; F Arminger; R Schaberl-Moser; H Samonigg; T Stojakovic; A Gerger
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

10.  The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.

Authors:  Lu-Ning Zhang; Weiwei Xiao; Pu-Yun OuYang; Kaiyun You; Zhi-Fan Zeng; Pei-Rong Ding; Zhi-Zhong Pan; Rui-Hua Xu; Yuan-Hong Gao
Journal:  Tumour Biol       Date:  2015-05-21
View more
  11 in total

1.  Novel hematological biomarkers predict survival in renal cell carcinoma patients treated with nephrectomy.

Authors:  Paweł Rajwa; Marcin Życzkowski; Andrzej Paradysz; Monika Slabon-Turska; Kamil Suliga; Kamil Bujak; Piotr Bryniarski
Journal:  Arch Med Sci       Date:  2017-09-21       Impact factor: 3.318

2.  Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis.

Authors:  Wen-Kai Xia; Xia Wu; Tang-Hong Yu; Yu Wu; Xia-Juan Yao; Hong Hu
Journal:  Onco Targets Ther       Date:  2016-05-09       Impact factor: 4.147

3.  Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma.

Authors:  Ying-Fen Hong; Zhan-Hong Chen; Li Wei; Xiao-Kun Ma; Xing Li; Jing-Yun Wen; Tian-Tian Wang; Xiu-Rong Cai; Dong-Hao Wu; Jie Chen; Dan-Yun Ruan; Ze-Xiao Lin; Qu Lin; Min Dong; Xiang-Yuan Wu
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

4.  Preoperative Lymphocyte-Monocyte Ratio Ameliorates the Accuracy of Differential Diagnosis in Non-Metastatic Infiltrative Renal Masses.

Authors:  Jang Hee Han; Young Eun Yoon; Sook Young Kim; Young In Cho; Koon Ho Rha; Young Deuk Choi; Woong Kyu Han
Journal:  Yonsei Med J       Date:  2017-03       Impact factor: 2.759

5.  The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xuemin Wang; Shiqiang Su; Yuanshan Guo
Journal:  Oncotarget       Date:  2017-09-20

6.  Predictive value of preoperative monocyte-lymphocyte ratio among patients with localized clear renal cell carcinoma of ≤7 cm on preoperative imaging.

Authors:  Ahmed Elghiaty; Jongchan Kim; Won Sik Jang; Jee Soo Park; Ji Eun Heo; Koon Ho Rha; Young Deuk Choi; Won Sik Ham
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

7.  Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis.

Authors:  Jialin Li; Yusheng Cheng; Zhigang Ji
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

8.  High lymphocyte‑to‑monocyte ratio is associated with low α‑fetoprotein expression in patients with hepatitis B virus‑associated hepatocellular carcinoma.

Authors:  Haixia Wang; Yu Xiang; Xinyu Li; Shuang Liu; Linxiu Liu
Journal:  Mol Med Rep       Date:  2020-07-29       Impact factor: 2.952

9.  Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy.

Authors:  Ding Peng; Cui-Jian Zhang; Qi Tang; Lei Zhang; Kai-Wei Yang; Xiao-Teng Yu; Yanqing Gong; Xue-Song Li; Zhi-Song He; Li-Qun Zhou
Journal:  BMC Urol       Date:  2018-03-15       Impact factor: 2.264

10.  Prognostic value of preoperative lymphocyte-to-monocyte ratio in gallbladder carcinoma patients and the establishment of a prognostic nomogram.

Authors:  Yan Deng; Ming-Fang Xu; Feng Zhang; Xiao Yu; Xue-Wen Zhang; Zhen-Gang Sun; Shuai Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.